Company Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy.
In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials.
The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Pasadena, California.
| Country | United States |
| Founded | 2001 |
| IPO Date | Jun 16, 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 711 |
| CEO | Christopher Anzalone |
Contact Details
Address: 177 East Colorado Boulevard, Suite 700 Pasadena, California 91105 United States | |
| Phone | 626 304 3400 |
| Website | arrowheadpharma.com |
Stock Details
| Ticker Symbol | ARWR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000879407 |
| CUSIP Number | 04280A100 |
| ISIN Number | US04280A1007 |
| Employer ID | 46-0408024 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher R. Anzalone Ph.D. | Chairman, Chief Executive Officer and President |
| Patrick O'Brien J.D., PharmD | Chief Operating Officer, General Counsel and Secretary |
| Dr. James C. Hamilton M.D., MBA | Chief Medical Officer and Head of Research & Development |
| Dr. Mark M. Davis Ph.D. | Founder and Founder and Director of Insert Therapeutics Inc & Calando |
| Daniel J. Apel | Chief Financial Officer |
| Dr. Vincent Anzalone CFA | Head of Investor Relations and Vice President |
| Howard Lovy | Director of Communications |
| Dr. Bruce D. Given M.D. | Chief Medical Scientist |
| Dr. Mark Seefeld | Head of Toxicology and Vice President |
| Aaron Tan | Head of Tax |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2025 | 144 | Filing |
| Nov 28, 2025 | 144 | Filing |
| Nov 25, 2025 | 10-K | Annual Report |
| Nov 25, 2025 | 8-K | Current Report |
| Nov 18, 2025 | 8-K | Current Report |
| Oct 10, 2025 | 10-K/A | [Amend] Annual report |
| Oct 1, 2025 | 144 | Filing |
| Sep 12, 2025 | 144 | Filing |
| Sep 12, 2025 | 8-K | Current Report |
| Sep 11, 2025 | 8-K | Current Report |